Initial two years of experience with the AAO National Eyecare Outcomes Network (NEON) cataract surgery database.

PURPOSE: To report the results of the first 2 years of experience with an American Academy of Ophthalmology (AAO) cataract surgery registry; to compare patient characteristics, operative procedures, and patient outcomes observed in the registry to those observed in the Cataract PORT study; and to discuss the current shortcomings and potential benefits of a national cataract surgery registry. DESIGN: Observational study of episodes of cataract surgery reported by a self-selected sample of 249 ophthalmologists. PARTICIPANTS: Seven thousand six hundred twenty-six patients undergoing cataract surgery during 1996 and 1997. METHODS: Beginning in January 1996, participation in the AAO cataract surgery registry was offered to all ophthalmologists. Participants could use software or paper data collection forms to submit a common set of data regarding patients' demographics, preoperative ophthalmologic history, physical examination and test results, functional status and symptoms, intraoperative procedures and events, and postoperative outcomes for all patients undergoing first or second eye cataract surgery. Data were transmitted to a central database, where they were aggregated and analyzed. Findings were compared with those observed in the Cataract PORT study, which was conducted in 1991 and 1992. RESULTS: Between January 1, 1996, and February 28, 1998, 249 ophthalmologists submitted data on at least one patient who underwent cataract surgery. A total of 7626 patients undergoing first or second eye surgery were enrolled, with all preoperative, intraoperative, and postoperative data forms submitted for 3342 patients (44%). The preoperative characteristics of patients reported to National Eyecare Outcomes Network (NEON) were similar to those of patients enrolled in the Cataract PORT study except for a higher reported prevalence of ocular comorbidity in NEON patients. Use of retrobulbar anesthesia was reported far less commonly, and use of topical anesthesia, phacoemulsification, and foldable intraocular lenses was reported far more often for NEON than for Cataract PORT study patients. Patient outcomes reported to NEON were similar to those observed in the Cataract PORT study. MAIN OUTCOME MEASURES: Visual acuity, VF-14, Cataract Symptom Score, surgical complications. CONCLUSIONS: During the first 2 years of NEON, ophthalmologist participation in the NEON cataract surgery database was low and consisted of a self-selected and likely nonrepresentative sample of ophthalmologists. The representativeness of patients for whom data were reported is unknown. In addition, complete data were submitted on only a minority of patients who were enrolled. Even so, the preoperative characteristics of patients on whom data were submitted to NEON were similar to those of patients enrolled in the Cataract PORT study. The initial experience with NEON demonstrates that it is technically possible to collect clinical data from, and report aggregated results to, practicing clinicians' offices. In addition, at least some practicing clinicians are willing to spend the time required to participate in the NEON registry. The NEON cataract surgery database thus has the potential to provide a practical means for tracking practice patterns and patient outcomes in real time. If a representative sample of physicians was willing to contribute data systematically and accurately over time, initiatives such as NEON could provide a means for professional societies and physicians to play a leadership role in defining and monitoring quality of care.

Clinical experience of trabeculotomy for the surgical treatment of aniridic glaucoma.

OBJECTIVE: The purpose of this study is to determine the efficacy of initial trabeculotomy in the patient with aniridic glaucoma. DESIGN: Clinical charts were reviewed. PARTICIPANTS: Twenty-nine eyes of 16 patients with aniridia were studied. INTERVENTION: Glaucoma surgery was performed. As an initial procedure, trabeculotomy was performed in 12 eyes, other surgery was performed in 17 eyes (trabeculectomy, 5; goniotomy, 5; other, 7). MAIN OUTCOME MEASURES: Success was defined as an intraocular pressure (IOP) of 21 mmHg or lower, and no further surgery was performed. RESULTS: Ten (83%) of 12 eyes obtained IOP control after first (6 eyes) or second (4 eyes) trabeculotomy with a mean follow-up period of 9.5 years. Five eyes maintained visual acuity of 20/40 to 20/200. No serious complications were found after trabeculotomy. Three (18%) of 17 eyes were controlled with the first glaucoma surgery other than trabeculotomy (goniotomy, trabeculectomy, trabeculectomy combined with trabeculotomy, and Molteno implant). Good IOP control was obtained in 8 (47%) of 17 eyes after several surgeries with a mean follow-up period of 10.4 years. Four of 17 eyes became phthisical. CONCLUSION: This study suggests that trabeculotomy is the preferred initial operation for uncontrolled glaucoma with aniridia.

Update on the subconjunctival THC:YAG (holmium) laser sclerostomy Ab externo clinical trial: a 4-year report.

BACKGROUND AND OBJECTIVE: This is a follow-up report on 103 THC:YAG (holmium) sclerostomies ab externo performed on 87 eyes of 81 patients. PATIENTS AND METHODS: The patients received pulse energies of 0.06 to 0.13 J (mean total energy 4.4 +/- 3.3 J, range 0.6 to 17.1 J). RESULTS: The estimated success rates with or without medication, and allowing a second procedure, were 44% at 2 years and 36% at 4 years. The mean preoperative intraocular pressure (IOP) was 29.7 +/- 11.4 mm Hg, and the mean postoperative IOP in the successful patients was 13.6 +/- 4.6 mm Hg (P < .01). Hypotony and iris incarceration were the most frequent early complications. CONCLUSIONS: Although holmium laser sclerostomy is a relatively straightforward procedure and offers some advantages over standard trabeculectomy in select cases, it currently has a number of drawbacks that limit its use.

Trabeculectomy with intraoperative sponge 5-fluorouracil.

PURPOSE: To retrospectively assess the outcome of trabeculectomy surgery performed using intraoperative sponge 5-fluorouracil (5-FU) (50 mg/ml). METHODS: Trabeculectomy with intraoperative sponge 5-FU was performed on 140 eyes of 119 patients. The reduction in intraocular pressure (IOP), the number of supplementary postoperative injections, and any treatment complications were noted. RESULTS: The mean preoperative IOP was 25.7 +/- 8.6 mmHg. The mean postoperative IOP was 12.5 +/- 5.7 mmHg with a mean IOP reduction of 52 percent (P < 0.0001). One hundred twenty-one (86.4 percent) eyes required no postoperative glaucoma medications, with the mean number of glaucoma medications dropping from 2.5 +/- 1.1 before operation to 0.3 +/- 0.8 after operation (P < 0.001). One hundred five eyes received a mean of 5.3 +/- 2.7 postoperative 5-FU injections. There was no significant difference in final IOP or success rate between low- and high-risk eyes, but high-risk eyes seemed to require supplementary postoperative 5-FU. Corneal epithelial damage arose in 52 (37 percent) eyes and correlated strongly with postoperative 5-FU supplementation. CONCLUSION: Intraoperative sponge 5-FU is a reasonably safe and effective adjunct to trabeculectomy surgery.

Update of the subconjunctival THC:YAG (holmium) laser sclerostomy ab externo clinical trial: 30-month report.

A THC:YAG laser (thulium, holmium, chromium-doped YAG crystal) was used to create 93 thermal sclerostomies ab externo in 81 glaucomatous eyes of 76 patients. Pulse energies of 80 to 120 mJ were used, with a repetition rate of 5 pulses per second. Total energy levels to produce full-thickness sclerostomies ranged from 1.4 to 7.2 J. Estimated probability of success was 0.66 at 12 months and 0.57 up to 30 months. The mean intraocular pressure in the successful cases was 12.8 +/- 4.0 mm Hg.

Repeatability of the glaucoma-scope measurements of optic nerve head topography.

The Glaucoma-Scope is designed to measure the topography of the optic nerve head. Depth measurements are reported as a grid of cells where each value represents the average depth of an area 55 +/- 100 mum in size. The Glaucoma-Scope was tested on 10 normal and 18 glaucomatous subjects, >40 years of age. Two separate visits were simulated for each patient. To estimate measurement variability, depth values were analyzed in groups of 25 cells, comprising "areas of interest." A components of variance analysis was used to compare the variability of the difference between the depth of an area measured at the first and second visits. The analysis yields within visit standard deviation of the difference between depth measurements taken within the same visit (Sw), the standard deviation of the difference between depth measurements taken at separate visits (Sb), and the total standard deviation of the difference between depth measurements (Sd). For flat areas outside the optic nerve head, Sd = 11.68 mum. For flat areas within the optic nerve head, Sd = 17.91 mum. For areas at the bottom of the cup, which includes sloped areas, Sd = 32.01 mum. For sloped areas within the optic nerve head, Sd = 20.78 mum. For areas over a vessel, Sd = 34.76 mum. The mean standard deviation of a single pixel in the Glaucoma-Scope measurement is 15.42 mum. The Glaucoma-Scope measurements are highly reproducible for both healthy and glaucomatous subjects. Local variability in depth measurements should be considered when evaluating change in optic nerve head topography.

Subconjunctival THC:YAG ("holmium") laser thermal sclerostomy ab externo. A one-year report.

BACKGROUND: Laser sclerostomy can be performed in a less-invasive manner than standard filtering surgery. Longer wavelengths in the infrared range have water-absorptive characteristics that facilitate perforation of the sclera. The goal was to perform laser sclerostomy ab externo to avoid intraocular instrumentation and minimize conjunctival trauma. METHODS: A thulium, holmium, chromium-doped:YAG (THC:YAG) crystal laser was used to create thermal sclerostomies in 49 glaucomatous eyes of 46 patients. The laser is a long-pulsed (300-microsecond), compact, self-contained, solid-state laser operating in the near infrared (2.1 microns). Energy was delivered via a specially designed 22-gauge (712-microns) optic probe that emits energy at a right angle to the long axis of the fiber. Pulse energies of 80 to 120 mJ were used. Total energy levels to produce full-thickness sclerostomies ranged from 1.4 to 7.2 J. Subconjunctival 5-fluorouracil (5-FU) injections were administered in 46 eyes. Success was defined as an intraocular pressure (IOP) of less than or equal to 22 mmHg with or without medications. For eyes in which preoperative IOP was less than or equal to 22 mmHg, success was defined as a decrease in IOP of greater than or equal to 30%. RESULTS: Estimated probability of success allowing for one retreatment was 0.75 at 6 months and 0.68 at 12 months. Mean IOP of successful cases was 13.3 mmHg at both 6 and 12 months. Twelve cases failed within the initial 6 months, and two additional cases failed by 12 months. CONCLUSION: THC:YAG ("holmium") laser thermal sclerostomy is an alternative to other full-thickness filtration procedures. Further evaluation and understanding will define its ultimate role in glaucoma management.

Laser sclerostomy for the management of glaucoma.

Laser sclerostomy can be performed in a less invasive manner than standard filtering surgery. Recent studies have explored the use of laser energy of varying wavelengths, properties, and tissue interaction to create thermal sclerostomies. Several methods deliver laser energy by mirrored contact lenses to the internal face of the filtration angle or by fiberoptic cables for ab interno or ab externo sclerostomy formation. Certain laser techniques can be performed outside the standard operating room, in a clinic or minor surgery room. This article reviews the various laser sclerostomy techniques currently being investigated.

Filtering seton implant for glaucoma: initial animal trial.

A newly developed silicone filtering seton device was implanted in each of five eyes of four rhesus monkeys after they had undergone extensive argon-laser trabeculoplasty to raise their intraocular pressure (IOP). One animal (one implant eye) was killed at 6 weeks. The other three animals (four implant eyes) were observed for 17 to 24 months following implantation surgery. Mild to moderate postoperative inflammation subsided during the first postoperative week. The eyes remained quiet throughout the remainder of follow up. The postoperative IOPs varied between 18% and 70% of the IOPs at the time of implant surgery. In the three monkeys that had unilateral surgery, the IOP at the final follow-up measurement was equal to or lower than the IOP in the unoperated fellow eye. In the monkey that had bilateral surgery, both of the final IOPs were lower than the preoperative ones.

Holmium laser sclerostomy in glaucoma management: a new tool for an old procedure.

A THC: YAG laser (thulium, holmium, chromium doped YAG crystal) was used to create thermal sclerostomies in 49 glaucomatous eyes of 46 patients. The laser is a long-pulsed (300 microseconds), compact, self contained, solid state laser operating in the near infrared (2.1 mu). A 1 mm conjunctival stab incision was made 12 mm away from the sclerostomy site to allow entry of a specially designed 22-gauge (712 mu) optic probe that delivers energy at a right angle to the long axis of the fiber. Probe insertion produced minimal disturbance of the conjunctiva. Pulse energies of 80 mJ tot 120 mJ were used with a repetition rate of 5 pulses/sec. Total energy levels to produce full-thickness sclerostomies ranged from 1.4 to 7.2 J. Subconjunctival 5-fluorouracil injections were administered in 46 eyes. Estimated probability of success was 74% at 6 months and 67% at 12 months. Mean intraocular pressure of successful cases was 13.3 mmHg at both both 6 months & 12 months. Twelve cases failed within the initial 6 months, and two additional cases failed by 12 months.

Trabeculodialysis for inflammatory glaucoma: a review of 25 cases.

We reviewed the results following trabeculodialysis in 25 eyes of 22 patients with secondary glaucoma due to chronic anterior uveitis. After 1 year, intraocular pressure (IOP) was uncontrolled (greater than 21 mm Hg) in 11 eyes (44%). Trabeculodialysis controlled IOP (less than 21 mm Hg) in 14 eyes (56%), with an average follow up of 52 months (range, 12 to 151 months). Sixteen eyes (64%) were aphakic, but did no worse than the phakic eyes. One eye developed a subchoroidal hemorrhage 3 days postoperatively which required drainage. No other serious complications were encountered. Trabeculodialysis is a safe procedure which can achieve pressure control in these difficult eyes.